Treatment
Platinum chemotherapy clinical trials
We’re tracking 118 recruiting studies that include Platinum chemotherapy, each written for real people, not researchers, below.
Recruiting studies
- NCT06924606RecruitingPhase 2
Testing JS207 for advanced lung cancer after prior treatments
This trial tests a new drug called JS207 for people with advanced non-small cell lung cancer (NSCLC) that has gotten worse after standard treatments like chemotherapy and immunotherapy. It aims to see if JS207 can help shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT07251582RecruitingPhase 3
Comparing infusion timing for lung cancer immunotherapy before surgery
This trial tests whether the timing of immunotherapy infusion before surgery improves how well the tumor responds in people with stage II to III non-small cell lung cancer. It combines immunotherapy with standard chemotherapy to shrink the tumor before it is removed.
Changsha, HunanAges 18–75 - NCT07018622RecruitingPhase 2
Protecting kidneys from platinum chemotherapy damage
This trial tests a way to protect your kidneys while you receive platinum-based chemotherapy (cisplatin or carboplatin) for a solid tumor. It may help reduce the risk of kidney damage so you can complete your treatment more safely.
México, TlalpanAges 18 years+ - NCT06491862Recruiting
Lung cancer care after chemo in Brazil
This study looks at how doctors in Brazil treat non-squamous non-small cell lung cancer after platinum chemotherapy stops working. It aims to understand real-world outcomes and help improve future care.
Belo Horizonte, Minas GeraisAges 18 years+ - NCT07502300RecruitingPhase 3
New drug combo for advanced small cell lung cancer
This trial tests a new drug combination (BL-B01D1 plus immunotherapy) as a first treatment for people with advanced small cell lung cancer. It may be an option if you haven't had treatment yet and are healthy enough for chemotherapy.
Zhengzhou, HenanAges 18 years+ - NCT07582315RecruitingPhase 3
BL-B01D1 for advanced biliary tract cancer after prior treatments
This study tests a new drug called BL-B01D1 against standard treatment options for patients with advanced biliary tract cancer (cancer of the bile ducts) that has stopped responding to platinum chemotherapy and immunotherapy. The drug is designed to target and destroy cancer cells more effectively.
Beijing, Beijing MunicipalityAges 18–75 - NCT07680764RecruitingPhase 2
Imzokitug plus pumitamig and chemo for first-line advanced lung cancer
This trial tests a new combination of drugs (imzokitug, pumitamig, and platinum-doublet chemotherapy) as a first treatment for advanced or metastatic non-small cell lung cancer that has not spread to the brain. The goal is to see if adding imzokitug makes the standard treatment work better.
Athens, GeorgiaAges 18 years+ - NCT07554456RecruitingPhase 2/Phase 3
New Drug Combination for Advanced Esophageal Cancer
This trial tests a new drug called BL-B01D1 combined with an immune therapy (tislelizumab) and sometimes chemotherapy against standard chemotherapy for esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if this new combination works better and is safer than current treatment.
Beijing, Beijing MunicipalityAges 18–75 - NCT04324151Recruiting
Pembrolizumab plus chemotherapy for lung cancer that may be removed
This trial tests whether adding pembrolizumab (an immune therapy) to standard chemotherapy helps people with certain non-squamous lung cancers that doctors think might be surgically removed. You might be considered if your planned treatment involves a “double platinum” chemotherapy or crizotinib and your cancer is potentially resectable.
Changsha, HunanAges 18 years+ - NCT04486833RecruitingPhase 1/Phase 2
Genetic-targeted drug plus gene medicine for EGFR lung cancer
This trial studies a gene-based treatment added to osimertinib (a targeted lung cancer pill) for advanced EGFR-mutant lung cancer that has started growing again on osimertinib. It may help by attacking the cancer with both its usual target treatment and an added genetic approach.
Los Angeles, CaliforniaAges 18 years+ - NCT05188859RecruitingPhase 2
Testing sintilimab, anlotinib, and chemo for pleural mesothelioma
This Phase 2 study tests whether adding three medicines—sintilimab, anlotinib, and standard platinum chemo—can control malignant pleural mesothelioma that cannot be removed by surgery. It may help shrink tumors and slow disease progression, but you must meet specific health and prior-treatment requirements.
Taiyuan, ShanxiAges 18 years+ - NCT05222971RecruitingPhase 2
Olaparib, with or without immunotherapy, for DNA-repair biliary cancer
This Phase 2 study tests olaparib (a targeted anti-cancer pill) alone or with durvalumab (an immunotherapy) for biliary tract cancers that have specific DNA repair gene changes. It’s for people whose cancer has continued after standard platinum chemotherapy, aiming to slow or control the disease.
SeoulAges 19 years+ - NCT05284539RecruitingPhase 2
Chemo plus immunotherapy for mutated advanced lung cancer
This trial studies whether combining platinum chemotherapy with immune “checkpoint” medicine works better for people with stage IV lung cancer that has EGFR, ALK, or ROS1 mutations. It focuses on tumors that have grown again after first-line treatment.
Changsha, HunanAges 18 years+ - NCT05295212RecruitingPhase 2
Atezolizumab plus chemo before surgery for lung cancer
This trial studies whether adding atezolizumab (an immune medicine) to standard platinum-based chemotherapy before surgery can improve outcomes for operable stage II–IIIB non-small cell lung cancer. The goal is to shrink the tumor and increase the chance the cancer can be removed with better results.
Changsha, HunanAges 18 years+ - NCT05363319Recruiting
Cemiplimab study in adults with advanced lung cancer
This observational study looks at how well cemiplimab works and how safe it is for adults with advanced non-small cell lung cancer in everyday care in Europe. It mainly follows patients already prescribed cemiplimab, and asks them to complete questionnaires.
Klagenfurt, CarinthiaAges 18 years+ - NCT05487391RecruitingPhase 3
QL1706 plus chemo after lung cancer surgery
This trial studies whether a study drug called QL1706 added to standard platinum chemotherapy can lower the chance of lung cancer coming back after surgery. It targets people with stage II to IIIB non-small cell lung cancer who have had their tumor fully removed.
ShanghaiAges 18 years+ - NCT05657873RecruitingPhase 2
Targeted radiation for metastatic lung cancer with liver spread
This trial studies whether adding targeted radiation to the liver (small-area, high-precision radiation) can help people with stage IV non-small cell lung cancer. Participants also start standard “anti–PD-1/PD-L1” immunotherapy (with chemotherapy in some cases).
Miami, FloridaAges 18 years+ - NCT06123884RecruitingPhase 2/Phase 3
BAT1308 plus chemotherapy for PD-L1-positive cervical cancer
This clinical trial tests a new combination therapy (BAT1308 plus chemotherapy, with or without Avastin) for women with advanced cervical cancer that is PD-L1-positive and has not been previously treated with systemic therapy. The goal is to see if this combination can shrink tumors or slow disease progression.
Wuhan, HubeiAges 18–70 - NCT06311968RecruitingPhase 2
Proton radiation after surgery for thymus tumors
This trial tests a type of precise radiation called proton therapy after surgery for thymus tumors. It may help reduce the chance of the tumor coming back while limiting side effects to nearby organs.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06313541RecruitingPhase 2
Adaptive radiation with immunotherapy for advanced lung cancer
This trial is testing a combination of immunotherapy and targeted radiation for people with advanced lung cancer that has no targetable gene changes. The goal is to see if adjusting radiation based on how well the tumor responds can improve outcomes.
ShanghaiAges 18 years+ - NCT06424899RecruitingPhase 2
Chemoimmunotherapy before and after chemoradiation for stage III lung cancer
This study tests whether combining chemotherapy with immunotherapy before and after chemoradiation helps people with stage III lung cancer that can be removed by surgery. It might improve how well treatment works and reduce the chance of cancer coming back.
Hangzhou, ZhejiangAges 18–75 - NCT06621563RecruitingPhase 1
Study of HS-20117 Combination Therapy for Advanced Solid Tumors
This early-phase trial tests a new drug (HS-20117) combined with other drugs for people with advanced solid tumors. It aims to see if the combination is safe and effective, especially for cancers that have not responded to other treatments.
TianjinAges 18–75 - NCT06623656RecruitingPhase 2
Pre-surgery treatment comparison for non-small cell lung cancer
This trial compares two treatment approaches before surgery for non-small cell lung cancer (NSCLC): radiation plus immunotherapy versus chemotherapy plus immunotherapy. The goal is to see which combination works better to shrink the tumor before it is removed.
New York, New YorkAges 18 years+ - NCT06668961RecruitingPhase 2
New combo therapy for head and neck cancer that has returned or spread
This trial is testing a combination of two targeted drugs (SI-B001 and SI-B003) plus chemotherapy as a first treatment for head and neck squamous cell carcinoma that has come back or spread to other parts of the body. The goal is to see if this combination works better than standard treatment.
Shanghai, Shanghai MunicipalityAges 18–75
Common questions
- Are there clinical trials studying Platinum chemotherapy?
- Yes. Clin2 currently lists 118 recruiting studies that include Platinum chemotherapy, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Platinum chemotherapy trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Platinum chemotherapy an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Platinum chemotherapy or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.